If you have been paying attention to Tempus and its development in Chicago, Illinois, then you are likely aware of the company’s May 2019 events with regards to raising capital. This company and Eric Lefkofsky, who actually was the 2016 creator of it, bolstered the status of Tempus among other health technology startups by attracting investors like Franklin Templeton during this period of time, as well as Novo Holdings. These two, and a few other Tempus investors, brought in, to the delight of Eric Lefkofsky, $200 million, which brought his total capital with this organization to an estimated $500 million. For the past four years, the center of Mr. Lefkofsky’s focus has been using the strengths of genomic sequencing tech in his passionate startup, which seeks to fight cancer in a technological way.
Although his genomic sequencing startup has thus far been used to plan tumor treatments, there are naturally other important uses for the Tempus group’s abilities in the sphere of genomic sequencing. Diabetes has been noted as a potential genomic sequencing focus, and so has depression. Towards this goal of expanding Tempus beyond the narrow field of cancer, Eric Lefkofsky chose to enter into agreements with the powerful CVS, as well as the lesser-known laboratory for biomarker profiling, AKESOgen. Concerning AKESOgen, this agreement took the form of an acquisition, while the CVS agreement was simply a partnership. Pharmaceutical strategies seem to be integrated into the Tempus future, and Mr. Lefkofsky is taking steps towards that Tempus future already. Click here.